

Ayuda Investigador AECC 2025

Adjudicaciones

Dra. María del Carmen Ochoa

Cancer Center Clínica Universidad de Navarra (UNAV-CCUN)

Synergy of the oncolytic adenovirus Delta-24-RGD with a novel adeno-associated virus-based platform in pediatric osteosarcoma treatment

Dra. Isabel García

Vall d'Hebron Instituto de Oncología (VHIO)

The next generation of CDK-targeted therapies (NEXT-CDKs)

Dra. Victoria da Silva

Fundació Sant Joan de Déu

Deciphering Immunomodulatory Metabolic networks in Pediatric acute Leukemias (DIMPLE)

Dr. Marc García

Instituto de Salud Carlos III (ISCIII)

Overcoming anti-viral immunity to optimize viroimmunotherapy for pediatric gliomas

Dr. Aitor Manteca

Centro de Investigación Cooperativa en Biomateriales (CIC biomaGUNE)

ImmunoDrop: Innovative droplet-based microfluidic technologies for immunopeptide discovery

Dra. María Elena López

Centro Andaluz de Biología Molecular y Medicina regenerativa (CABIMER)

Innovative technological approaches to enhance therapeutical effect and prevent resistance by targeting tumor heterogeneity in breast cancer (TechCare)

Dr. Pierre Levy

Vall d'Hebron Instituto de Oncología (VHIO)

Decoding anti-tumor immunity through high-throughput cancer antigen and TCR screens

Dra. Isabel Calvo

Cancer Center Clínica Universidad de Navarra (CIMA-CCUN)

Deciphering the role of the non-hematopoietic BM microenvironment in MGUS progression to smoldering and multiple myeloma through single-cell and spatial transcriptomics

Suplentes

Dra. Isabel Puig

Vall d'Hebron Instituto de Oncología
(VHIO)

Identifying new pharmacological targets
and therapeutic strategies to treat
colorectal cancer persistence

Dra. Lucía García

Instituto de Investigación Marqués
de Valdecilla (IDIVAL)

Impact of deregulated MYC in the
biology of cutaneous T cell lymphomas.
Translational applications for diagnostics
and therapy

Dr. Joaquín Seras

Vall d'Hebron Instituto de
Investigación (VHIR)

Mining tumor extracellular vesicles (EV)
diversity in triple negative breast cancer
(TNBC)- NANOBEACONS with diagnostic
and prognostic value - MinEV

Dra. Alba Maiques

Fundació de Recerca Clínic
Barcelona-Institut d'Investigacions
Biomèdiques August Pi i Sunyer

Unraveling transcription factors driving
CLL proliferation and its impact on
treatment response

Dra. Vanesa Álvarez

Centro Singular de Investigación en
Medicina Molecular y
Enfermedades Crónicas (CiMUS)

Study of the lncRNAs involved in
cholangiocarcinoma development

Dr. Francesco Grussu

Vall d'Hebron Instituto de Oncología
(VHIO)

Histology-informed Magnetic Resonance
imaging for Precision Oncology
(HistoMR-PrecOnco) in hospital settings

Dra. Mireia Uribe

Fundació de Recerca Clínic
Barcelona-Institut d'Investigacions
Biomèdiques August Pi i Sunyer

Development of an artificial intelligence
algorithm based on the gut microbiota
composition and microbiome-derived
metabolome to predict response to
CAR-T cell therapy in multiple myeloma
patients